No abstract

Anti-IL-1 treatment is an effective alternative for controlling attacks and decreasing proteinuria in colchicine-resistant FMF patients.

BackgroundBehçet's disease does not have specific laboratory findings or a pathological physical examination sign. There are many suggested markers for inflammation in BD. Studies on this issue have shown that IL-6, IL-1β, TNF-α, thrombomodulin, E-selectin, VEGF, total homocysteine, α-1 antitrypsin, α-2 macroglobulin are the considered markers associated with BD. Recently, reports have concluded that the neutrophil/lymphocyte ratio (NLR) and mean platelet volume (MPV) are indicators for systemic inflammation. To the best of our knowledge, there is no research in the literature that evaluates both MPV and N/L ratio for patients with Behçet's disease.ObjectivesWith this retrospective study, we researched the effects of MPV and NLR on the activity of Behçet's disease and susceptibility to thrombosis.Methods186 patients with Behçet's disease, who met the inclusion criteria, were separated into two groups as following: 120 patients with active Behçet's disease (Group I) and 66 patients with inactive Behçet's disease (Group II). 79 healthy subjects as controls were included in the study.ResultsMPV was similar between all three groups. CRP was statistically higher in the active BD group when compared to the inactive BD group and the control group. CRP of the inactive BD and the healthy control group were similar. In addition, ESR was found higher than the control group in both active and inactive BD groups, whereas ESR of the active BD group was higher than the inactive BD group. N/L ratio was found statistically higher in the active BD group when compared to inactive BD and healthy control groups, while the N/L ratio of inactive BD and healthy control groups were found similar to each other. While MPV, CRP, and NLR didn't statistically differ between active BD subgroups with and without thrombosis, ESR was statistically and significantly higher in the active BD group with thrombosis when compared to the active BD group without thrombosis.Table 1.Study parameters in all groupsGroup I (n=120)Group II (n=66)Control (n=79)pMPV (f/L)8.16±1.098.39±0.868.47±0.870.66CRP (mg/L)0.51 (0.23-0.89)0.19 (0.04-0.36)0.13 (0.08-0.18)<0.001†ESR (mm/h)19.5 (12-20)13.0 (11-16)11.0 (9-13)<0.001‡NLR4.41 (2.77-6.20)1.82 (1.47-1.99)1.72 (1.32-2.04)<0.001††There was a statistically significant difference between group I with group II and group I with control but no statistically significant difference between group II and control.‡There was a statistically significant difference in all groups.ConclusionsThe data obtained from the present study showed that the patients with BD are exposed to chronic inflammation. And the N/L ratio may be a simple, inexpensive, and convenient diagnostic marker of active BD.Disclosure of InterestNone declared

Objective: The role of vitamin D in the etiopathogenesis of fibromyalgia and non-specific musculoskeletal pain is controversial. In our study, we aimed to investigate the effect of vitamin D therapy on quality of life in patients with fibromyalgia. Materials and Methods:Seventy patients diagnosed with fibromyalgia and 65 age-and sex-matched controls were included in the study. Patients were grouped as deficient (<20 ng/mL), inadequate (20-30 ng/mL), and sufficient (>30 ng/mL) according to the levels of vitamin D. Vitamin D replacement was performed for patients with deficiencies and inadequacies. Before and after vitamin D therapy, patients filled in the assessment tools, fibromyalgia impact questionnaire (FIQ), Arizona sexual experience scale (ASEX), Beck depression inventory (BDI), visual analog scale (VAS), and short form-36 (SF-36).Results: Vitamin D deficiencies and inadequacies were observed in 60% of the patients (n=42). Among patients with low and normal levels of vitamin D, no statistically significant difference was observed in their values. In scales examined after vitamin D replacement therapy, statistically significant differences were observed in the FIQ, BDI, VAS, and SF-36 compared with pre-treatment.

Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC. No proof was obtained for the uroprotective effect of mesna in our cohort.